

Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation
POST-ACM ERRATUM

This report was commissioned by the NIHR HTA Programme as project number 11/49

BMJ Technology
Assessment
Group

This document contains erratum identified following the appraisal committee meeting on 20th November 2012

The table below lists the page to be replaced in the original document and the nature of the change:

Page No.	Change
186	Incremental analysis presented in Table 94 updated
188	Incremental analysis presented in Table 98 updated

Treatment effectiveness

Table 94. Incremental results assuming stroke severity is independent of treatment received (equal to that observed with apixaban in ARISTOTLE)

Technologies	Total			Incremental			ICER (£/QALY) versus warfarin	ICER (£) Incremental
	Costs (£)	LYG	QALYs	Costs (£)	LYG	QALYs		
Warfarin	6,576.61	7.49	5.73	-	-	-	-	-
Dabigatran 150 mg & 110 mg	7,878.01	7.57	5.84	1,301.40	0.09	0.11	12,197.46	Extendedly dominated
Dabigatran 110 mg	8,082.11	7.54	5.81	204.10	-0.03	-0.03	Strictly dominated	
Rivaroxaban	8,315.84	7.58	5.85	233.73	0.04	0.04	15,134.81	Extendedly dominated
Apixaban	8,485.48	7.63	5.89	169.64	0.05	0.04	12,276.64	12,276.64

Abbreviations used in table: ICER, incremental cost-effectiveness ratio; LYG, life years gained; mg, milligram; QALYs, quality adjusted life-years.

Table 95. Incremental results assuming bleed type is independent of treatment received (equal to that observed with apixaban in ARISTOTLE)

Technologies	Total			Incremental			ICER (£/QALY) versus warfarin	ICER (£) Incremental
	Costs (£)	LYG	QALYs	Costs (£)	LYG	QALYs		
Warfarin	7,264.28	7.44	5.67	-	-	-	-	-
Dabigatran 150 mg & 110 mg	8,554.28	7.51	5.77	1,290.00	0.07	0.10	13,649.70	Extendedly dominated
Dabigatran 110 mg	8,753.10	7.50	5.74	198.82	-0.02	-0.02	Strictly dominated	
Rivaroxaban	8,903.21	7.53	5.79	150.11	0.04	0.05	14,118.78	Extendedly dominated
Apixaban	9,018.76	7.61	5.85	115.55	0.08	0.06	9,771.15	9,771.15

Abbreviations used in table: ICER, incremental cost-effectiveness ratio; LYG, life years gained; mg, milligram; QALYs, quality adjusted life-years.

Table 98. Incremental results following application of future stroke risks for patients who have experienced an MI

Technologies	Total			Incremental [†]			ICER (£/QALY) versus warfarin	ICER (£) Incremental
	Costs (£)	LYG	QALYs	Costs (£)	LYG	QALYs		
Warfarin	7,310.59	7.46	5.69	-	-	-	-	-
Dabigatran 150 mg & 110 mg	8,594.13	7.53	5.78	1,283.54	0.07	0.09	14,227.51	Extendedly dominated
Dabigatran 110 mg	8,838.16	7.50	5.75	244.03	-0.03	-0.03	Strictly dominated	
Rivaroxaban	8,904.31	7.55	5.80	66.16	0.05	0.06	14,094.24	Extendedly dominated
Apixaban	9,104.35	7.61	5.85	200.04	0.06	0.05	10,981.19	10,981.19

Abbreviations used in table: ICER, incremental cost-effectiveness ratio; LYG, life years gained; mg, milligram; QALYs, quality adjusted life-years.

Resource use and costs

Table 99. Incremental results following application of acute SE costs from dabigatran submission⁽⁴³⁾

Technologies	Total			Incremental			ICER (£/QALY) versus warfarin	ICER (£) Incremental
	Costs (£)	LYG	QALYs	Costs (£)	LYG	QALYs		
Warfarin	7169.07	7.47	5.70	-	-	-	-	-
Dabigatran 150 mg & 110 mg	8416.36	7.54	5.79	1247.29	0.07	0.09	13640.24	Extendedly dominated
Dabigatran 110 mg	8663.90	7.50	5.76	247.54	-0.03	-0.03	Strictly dominated	
Rivaroxaban	8759.28	7.55	5.81	95.38	0.05	0.05	14074.43	Extendedly dominated
Apixaban	8964.36	7.61	5.86	205.08	0.06	0.05	11012.05	11012.05

Abbreviations used in table: ICER, incremental cost-effectiveness ratio; LYG, life years gained; mg, milligram; QALYs, quality adjusted life-years.